Renal Cell Carcinoma
Specialty Channel

Featured Article
Pembrolizumab monotherapy as a first-line treatment showed promising antitumor activity in treatment-naive ccRCC patients.
Axitinib showed a better tumor response rate than nivolumab, according to a study comparing the 2 as second-line treatment in mRCC.
Which combo therapy regimen was approved by the FDA for the treatment of advanced RCC in January 2021?
The FDA has approved nivolumab plus cabozantinib for patients with advanced renal cell carcinoma.
A study including the largest metastatic RCC cohort to date has shown that ctDNA testing is viable and efficient for detecting genomic alterations in this patient population.
In the largest real-world study to date, researchers found cabozantinib effective in treating heavily pretreated patients with metastatic RCC.
Findings from a cohort study show ICI rechallenge yields reasonable safety and efficacy in patients with metastatic RCC.
Results from a phase II trial showed promising activity in pazopanib when given to mRCC patients after receiving ICIs.
Which therapy had a better safety profile and OS rate in the SAVOIR trial for papillary RCC?

News

Pembrolizumab monotherapy as a first-line treatment showed promising antitumor activity in treatment-naive ccRCC patients.
Axitinib showed a better tumor response rate than nivolumab, according to a study comparing the 2 as second-line treatment in mRCC.
The FDA has approved nivolumab plus cabozantinib for patients with advanced renal cell carcinoma.
A study including the largest metastatic RCC cohort to date has shown that ctDNA testing is viable and efficient for detecting genomic alterations in this patient population.

Interactive Features

Which combo therapy regimen was approved by the FDA for the treatment of advanced RCC in January 2021?
Which therapy had a better safety profile and OS rate in the SAVOIR trial for papillary RCC?
True or False: Pembrolizumab combined with bevacizumab was proven safe and active in a study of patients with metastatic clear cell renal cell carcinoma.
True or false: Ipilimumab plus nivolumab did not demonstrate activity in patients with metastatic RCC previously given immune checkpoint inhibitors.
Stay in the know.
OncNet Newsletter